Apoptose
Os inibidores da apoptose são compostos que previnem ou retardam o processo de morte celular programada, conhecido como apoptose. Esses inibidores são vitais no estudo dos mecanismos de sobrevivência celular e são usados para investigar doenças onde a apoptose é desregulada, como câncer, distúrbios neurodegenerativos e doenças autoimunes. Ao modular a apoptose, esses inibidores podem ajudar no desenvolvimento de terapias destinadas a controlar a morte celular. Na CymitQuimica, oferecemos uma ampla seleção de inibidores da apoptose de alta qualidade para apoiar sua pesquisa em biologia celular, oncologia e áreas relacionadas.
Subcategorias de "Apoptose"
- ASK(6 produtos)
- BCL(11 produtos)
- Caspase(125 produtos)
- FOXO1(3 produtos)
- IAP(66 produtos)
- Mdm2(12 produtos)
- PD-1/PD-L1(125 produtos)
- PDK(9 produtos)
- PERK(25 produtos)
- Serina/treonina quinase(15 produtos)
- Survivina(13 produtos)
- TNF(92 produtos)
- c-RET(51 produtos)
- p53(62 produtos)
Exibir 6 mais subcategorias
Foram encontrados 5598 produtos de "Apoptose"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
Topoisomerase II inhibitor 20 TFA
<p>TopoisomeraseII Inhibitor 20 TFA is a potent inhibitor of topoisomerase II with an IC50 of 0.98 µM. It can induce cell apoptosis and exhibits broad-spectrum anticancer activity.</p>Fórmula:C24H24F5N5O4SCor e Forma:SolidPeso molecular:573.54RET-IN-11
<p>RET-IN-11 selectively inhibits RET (IC50: 6.20 nM), promotes apoptosis, and hinders cell proliferation and migration.</p>Fórmula:C27H30FN9OCor e Forma:SolidPeso molecular:515.59CCT369260
CAS:<p>CCT369260 (compound 1), an orally active inhibitor targeting B-cell lymphoma 6 (BCL6), demonstrates anti-tumor efficacy with an IC50 value of 520 nM [1].</p>Fórmula:C24H31ClF2N6O2Cor e Forma:SolidPeso molecular:508.99Anticancer agent 65
CAS:<p>Anticancer agent 65: Effective on A549 cells, IC50 1.07 μM, halts S phase, triggers apoptosis, elevates p53/p21, causes ROS and MMP collapse.</p>Fórmula:C36H63NO5Cor e Forma:SolidPeso molecular:589.89WEHI-539
CAS:<p>WEHI-539 is a selective Bcl-XL inhibitor (IC50: 1.1 nM).</p>Fórmula:C31H29N5O3S2Pureza:98%Cor e Forma:SolidPeso molecular:583.72eIF4A3-IN-4
<p>eIF4A3-IN-4 is a novel inhibitor of eIF4A (IC50: 8.6 μM).</p>Fórmula:C24H20N2O5Cor e Forma:SolidPeso molecular:416.43mTOR/HDAC6-IN-1
<p>mTOR/HDAC6-IN-1 inhibits HDAC6 (IC50: 56 nM) & mTOR (IC50: 133.7 nM), may treat TNBC by inducing autophagy and apoptosis.</p>Fórmula:C20H20ClN5O2Cor e Forma:SolidPeso molecular:397.86Ganoderic acid R
CAS:<p>Ganoderic acid R: potent anticancer, induces apoptosis, cytotoxic to MDR and sensitive tumor cells.</p>Fórmula:C34H50O6Cor e Forma:SolidPeso molecular:554.76RWJ-56110
CAS:<p>protease-activated receptor-1 (PAR1) antagonist</p>Fórmula:C41H43Cl2F2N7O3Pureza:98%Cor e Forma:SolidPeso molecular:790.73Bcl-2-IN-6
<p>Bcl-2-IN-6 suppresses Bcl-2, upregulates p53/Bax/caspase-7, arrests cell cycle, and induces MCF-7 apoptosis; IC50s: MCF-7 20.91 μM, others <48 μM.</p>Fórmula:C25H24N4O5S2Cor e Forma:SolidPeso molecular:524.61Flizasertib
CAS:<p>Flizasertib is a serine/threonine kinase inhibitor that acts by inhibiting RIPK1, which has anti-inflammatory and therapeutic effects on immune disorders.</p>Fórmula:C15H14FN3OPureza:99.39% - 99.57%Cor e Forma:SolidPeso molecular:271.29Anticancer agent 53
CAS:<p>Anticancer agent 53 exhibits potent in vitro cytotoxicity, triggers apoptosis, halts S/G2/M cycle, and has antitumor effects without toxicity.</p>Fórmula:C31H25FN4O6SCor e Forma:SolidPeso molecular:600.62D-Cl-amidine hydrochloride
<p>D-Cl-amidine hydrochloride is a potent and highly selective inhibitor of PAD1. It exhibits excellent tolerance and does not induce significant toxicity [1].</p>Fórmula:C14H20Cl2N4O2Cor e Forma:SolidPeso molecular:347.24AQIM-I
CAS:<p>AQIM-I is a survivin inhibitor that reduces survivin expression and colony formation. It promotes reactive oxygen species (ROS) production, apoptosis, cell cycle arrest, DNA damage, and autophagy. Moreover, AQIM-I effectively inhibits nonsmall cell lung cancer cells A549, with an IC 50 value of 9 nM [1].</p>Fórmula:C17H13IN2O2Cor e Forma:SolidPeso molecular:404.20ZLHQ-5f
<p>ZLHQ-5f inhibits CDK2/Topo I, with IC50 of 0.145μM for CDK2/CycA2, and promotes apoptosis by arresting HCT116 cells in S phase.</p>Fórmula:C28H25N5O2Cor e Forma:SolidPeso molecular:463.53HDAC-IN-9
<p>HDAC-IN-9, a dual tubulin/HDAC inhibitor, impedes A549 cell invasion/migration and shows strong anti-tumor/angiogenic effects.</p>Fórmula:C33H38N2O4Cor e Forma:SolidPeso molecular:526.67hCAIX/XII-IN-5
<p>Coumarin 9a: Selective inhibitor of hCA IX/XII (Ki 93.3/85.7 nM), blocks cancer cell growth, and induces apoptosis.</p>Fórmula:C18H13NO3Cor e Forma:SolidPeso molecular:291.3RIPK1-IN-14
CAS:<p>RIPK1-IN-14 inhibits RIPK1 with 92 nM IC50 and reduces necrotic apoptosis in U937 cells.</p>Cor e Forma:SoildDPP-21
CAS:<p>DPP-21 is an inhibitor of microtubule protein polymerization (IC50: 2.4 μM). It exhibits antiproliferative activity against various cancer cell lines, with IC50 values of 0.38 nM (HCT116), 11.69 nM (B16), 5.37 nM (HeLa), 9.53 nM (MCF7), 8.94 nM (H23), and 9.37 nM (HepG2). DPP-21 induces cell cycle arrest at the G2/M phase of mitosis and subsequently triggers apoptosis in tumor cells by decreasing Bcl-2 while increasing pro-apoptotic protein Bax levels.</p>Fórmula:C17H16N4SCor e Forma:SolidPeso molecular:308.40Multi-kinase-IN-1
CAS:<p>Multi-kinase-IN-1, a powerful kinase inhibitor, exhibits antitumor properties by inducing cell apoptosis.</p>Fórmula:C35H36F2N6O6SCor e Forma:SolidPeso molecular:706.76Anticancer agent 14
<p>Anticancer agent 14: a potent breast cancer inhibitor; induces cell death, disrupts mito. membrane potential (IC50: 0.20-0.65 μM).</p>Fórmula:C29H34N2O3Cor e Forma:SolidPeso molecular:458.59AK-295
CAS:<p>AK 295, also known as CX 295, is a dipeptide inhibitor of alpha-ketoamide calpain.</p>Fórmula:C26H40N4O6Cor e Forma:SolidPeso molecular:504.62MB710
CAS:<p>MB710 is an amino-benzothiazole derivative that tightly binds to the Y220C pocket and stabilizes p53-Y220C in vitro.</p>Fórmula:C16H16IN3O3SPureza:99.02%Cor e Forma:SolidPeso molecular:457.29HDAC1-IN-5
<p>HDAC1-IN-5 inhibits HDAC1 (IC50=15 nM) & HDAC6 (IC50=20 nM), promotes apoptosis, damages chromatin, and reduces tumor growth in mice.</p>Fórmula:C20H21N3O2SCor e Forma:SolidPeso molecular:367.46MA242 free base
CAS:<p>MA242 free base is a dual MDM2/NFAT1 inhibitor that triggers apoptosis in pancreatic cancer cells.</p>Fórmula:C24H20ClN3O3SCor e Forma:SolidPeso molecular:465.95NVP-CGM097 sulfate
CAS:<p>NVP-CGM097 sulfate is a potent and selective inhibitor of MDM2 (hMDM2, IC50 of 1.7±0.1 nM).</p>Fórmula:C38H49ClN4O8SPureza:98%Cor e Forma:SolidPeso molecular:757.34Antitumor agent-76
CAS:<p>Antitumor agent-76 is a water-soluble, orally active, rapid-release prodrug of Triptolide that exhibits anticancer effects.</p>Fórmula:C28H36ClNO10Cor e Forma:SolidPeso molecular:582.04FLT3-ITD-IN-3
CAS:<p>FLT3-ITD-IN-3 (13v) is an orally active inhibitor of FLT3-ITD (internal tandem duplication of FLT3), which works by blocking FLT3 signaling. This inhibition leads to cell cycle arrest in the G0/G1 phase and induces apoptosis. The compound is currently employed in studies related to acute myeloid leukemia (AML).</p>Fórmula:C27H21ClF2N6O5Cor e Forma:SolidPeso molecular:582.943HDAC-IN-27 dihydrochloride
CAS:<p>HDAC-IN-27 dihydrochloride (Compound 11h) is a potent, orally active, HDACI class-selective inhibitor, with IC50 values ranging from 0.43 to 3.01 nM for HDAC1-3. This compound exhibits both in vivo and in vitro anticancer activity. HDAC-IN-27 shows significant antiproliferative effects against acute myeloid leukemia (AML) cell lines by inducing apoptosis and histone acetylation (AcHH3 and AcHH4). It is useful for research on acute myeloid leukemia (AML).</p>Fórmula:C20H24Cl2N4O2Cor e Forma:SolidPeso molecular:423.336Lepidozin G
<p>Lepidozin G blocks cancer growth (IC50=4.2-5.7μM) and triggers apoptosis in PC-3 cells via mitochondria.</p>Fórmula:C30H48O4Cor e Forma:SolidPeso molecular:472.7FKBP12 PROTAC dTAG-13
CAS:<p>FKBP12 PROTAC dTAG-13 is a PROTAC and selective degrader for target validation by splicing FKBP12 F36V with CRBN and thereby degrading FKBP12 F36V.</p>Fórmula:C57H68N4O15Pureza:97.31%Cor e Forma:SolidPeso molecular:1049.173-AP-Me
CAS:<p>3-AP-Me is the dimethyl derivative of the ribonucleotide reductase inhibitor 3-AP (SML0568). It activates the endoplasmic reticulum (ER) stress pathway by promoting eIF2α phosphorylation and upregulating gene expression of transcription factors ATF4 and ATF6, thereby inducing apoptosis. Additionally, 3-AP-Me activates cellular stress kinases c-Jun N-terminal kinase (JNK) and p38 mitogen-activated protein kinase, leading to the upregulation of spliced mRNA variant XBP1. It is applicable in cancer research.</p>Fórmula:C9H13N5SCor e Forma:SolidPeso molecular:223.298NLRP3-IN-78
CAS:<p>NLRP3-IN-78 (compound 21) is an NLRP3 inhibitor with a 46.72% inhibition rate of GSDMD-induced pyroptosis at 5 μM. It binds to the NLRP3 protein and prevents GSDMD-NT oligomerization. Additionally, NLRP3-IN-78 inhibits GSDMD cleavage and upstream NF-κB signaling, demonstrating anti-inflammatory activity.</p>Fórmula:C12H5Cl2N3O4S2Cor e Forma:SolidPeso molecular:390.222p53-MDM2-IN-6
CAS:<p>p53-MDM2-IN-6, an LSM-83177 hydrazone analog, acts as an efficacious p53-MDM2 inhibitor with an IC50 of 11.08 µg/mL. This compound inhibits the p53-MDM2 interaction leading to an increase in p-53 levels while concurrently decreasing GST enzyme expression. It halts the cell cycle at the S phase and induces early and late apoptosis (Apoptosis), exhibiting antiproliferative activity against the HT29 cell line with an IC50 of 10.44 µg/mL. p53-MDM2-IN-6 holds promise for research in colorectal cancer.</p>Fórmula:C17H17N3O4Cor e Forma:SolidPeso molecular:327.33HBV/HDV-IN-2
CAS:<p>HBV/HDV-IN-2 (Compd 143) functions as an inhibitor for HBV, HDV, and PD-1/PD-L1, demonstrating an EC 50 of 35 nM in T cell activation.</p>Fórmula:C38H44ClN7O5Cor e Forma:SolidPeso molecular:714.25Tubulin inhibitor 43
CAS:<p>Tubulin inhibitor 43 exhibits significant antitumor activity by impeding the proliferation and growth of cancer cells through the inhibition of β-microtubulin activity, ultimately inducing apoptosis [1].</p>Fórmula:C20H21NO6Cor e Forma:SolidPeso molecular:371.3806:0 PE
CAS:<p>06:0 PE (PE(6:0/6:0)) is a water-soluble phospholipid characterized by its short acyl chains. It possesses notable antitumor activity and can inhibit tumor progression in the body. Additionally, it exhibits antiproliferative and pro-apoptotic properties, and serves as a precursor for phosphatidylcholine and phosphatidylethanolamine.</p>Fórmula:C17H34NO8PCor e Forma:SolidPeso molecular:411.43JR5-26B
CAS:<p>JR5-26B is an orally active apoptosis (apoptosis) inducer. It induces cell death via copper-mediated apoptosis and necroptosis (necroptosis). JR5-26B exhibits antiproliferative activity against MIA PaCa-2, PANC-1, PAN02, SU.86.86, and KPC-2 cells, with IC50 values of 0.6, 4.4, 8.0, 1.1, and 3.4 μM, respectively.</p>Fórmula:C19H17FN6OCor e Forma:SolidPeso molecular:364.38HAC-Y6
CAS:<p>HAC-Y6 exerts its anticancer effects by inducing cell cycle arrest. It prompts apoptosis in COLO 205 cells with an IC50 of 0.52 µM.</p>Fórmula:C23H22N2O4Cor e Forma:SolidPeso molecular:390.43PI3K/AKT-IN-1
CAS:<p>PI3K/AKT-IN-1 is a dual inhibitor of PI3K and AKT with anti-cancer activity, inhibiting the PI3K/AKT pathway and inducing caspase 3-dependent apoptosis.</p>Fórmula:C23H23N5O4SPureza:99.84%Cor e Forma:SoildPeso molecular:465.53Pim-1 kinase inhibitor 10
CAS:<p>Pim-1 Kinase Inhibitor 10 (compound 13a) acts as both a competitive and non-competitive inhibitor of PIM-1/2 kinase, promoting cell apoptosis and displaying anticancer properties. Additionally, this compound triggers the activation of caspase 3/7 [1].</p>Fórmula:C21H13N3O3Cor e Forma:SolidPeso molecular:355.35TNF-α-IN-14
CAS:<p>TNF-α-IN-14, a potent TNFα inhibitor, exhibits a selective inhibition profile with an IC50 of 1.1 µM and demonstrates antiinflammatory properties (WO2001072735A2; compound 12) [1].</p>Fórmula:C22H26O6Cor e Forma:SolidPeso molecular:386.44DWP-05195
CAS:<p>DWP-05195 is a TRPV1 antagonist capable of inhibiting pain signal transduction. Additionally, it induces ER stress-dependent apoptosis in human ovarian cancer cells via the ROS-p38-CHOP pathway.</p>Fórmula:C18H10BrF3N4Cor e Forma:SolidPeso molecular:419.2Ferroptosis-IN-6
CAS:<p>Ferroptosis-IN-6 is an efficient ferroptosis inhibitor, protecting cells from cell death induced by ferroptosis inducers, and inhibiting STY-BODIPY oxidation.</p>Fórmula:C15H17NOPureza:99.84%Cor e Forma:SolidPeso molecular:227.3Topo I/COX-2-IN-1
<p>Topo I/COX-2-IN-1: potent dual inhibitor; IC50 0.24μM (COX-2), 4.42μM (Topo I); anti-cancer; induces apoptosis, halts migration.</p>Fórmula:C21H18ClFN2O3Cor e Forma:SolidPeso molecular:400.83Scytonemin
CAS:<p>Scytonemin, a cyanobacterial pigment, inhibits cancer cell growth by decreasing Plk1 activity, especially effective on U266 myeloma cells.</p>Fórmula:C36H20N2O4Cor e Forma:SolidPeso molecular:544.55GGTI-2154 hydrochloride
CAS:<p>GGTI-2154 hydrochloride: selective GGTase I inhibitor, IC50 21 nM, used in cancer research.</p>Fórmula:C24H29ClN4O3Cor e Forma:SolidPeso molecular:456.97Tubulin inhibitor 13
CAS:<p>Tubulin inhibitor 13 (E27), IC50 16.1 μM, blocks tubulin polymerization, cancer cell migration, and invasion, induces apoptosis.</p>Fórmula:C25H21N3O4Cor e Forma:SolidPeso molecular:427.45TOPOI/PARP-1-IN-1
CAS:<p>Compound B6, also known as TOPOI/PARP-1-IN-1, is a dual inhibitor targeting TOPOI and PARP, exhibiting low cytotoxicity and oral activity with a PARP1 IC 50 of 0.09 μM. This compound effectively inhibits cancer cell proliferation and migration, induces cell cycle arrest at the G0/G1 phase, and triggers apoptosis. In murine models, TOPOI/PARP-1-IN-1 demonstrated a tumor growth inhibition rate (TGI) of 75.4% [1].</p>Fórmula:C36H38Br2N4O2Cor e Forma:SolidPeso molecular:718.52eIF4E-IN-4
CAS:<p>eIF4E-IN-4 (Compound 33) is a selective inhibitor of the eukaryotic initiation factor 4E (eIF4E) with a biochemical activity value of 95 nM. It inhibits cap-dependent mRNA translation with an IC50 of 2.5 μM and is applicable in research on breast cancer, colon cancer, and head and neck cancer.</p>Fórmula:C20H19ClN5O5PCor e Forma:SolidPeso molecular:475.822AZD0424
CAS:<p>AZD0424: oral Src/Abl kinase inhibitor; potential anticancer; induces apoptosis, cell cycle arrest in lymphoma.</p>Fórmula:C25H29ClN6O5Pureza:98%Cor e Forma:SolidPeso molecular:528.99HDAC/PSMD14-IN-1
CAS:<p>HDAC/PSMD14-IN-1 is a derivative of gambogic acid. It serves as an orally active dual inhibitor targeting PSMD14 and HDAC1, with IC50 values of 238.7 nM and 141.2 nM, respectively. The compound exhibits significant cytotoxicity against ESCC cell lines (IC50: 30-250 nM) and effectively reverses epithelial-mesenchymal transition (EMT). Additionally, HDAC/PSMD14-IN-1 can induce apoptosis. In KYSE30 cell xenograft models in mice, it displays antitumor activity. HDAC/PSMD14-IN-1 is useful for researching esophageal cancer treatment.</p>Fórmula:C20H24N4O3S2Cor e Forma:SolidPeso molecular:432.56PD-1/PD-L1-IN-55
CAS:<p>PD-1/PD-L1-IN-55 (compound D6) is a potent PD-1/PD-L1 inhibitor with an IC50 of 4.8 nM. It enhances IFN-γ secretion and decreases the proportion of late apoptosis due to PD-L1.</p>Fórmula:C25H23ClN2O3Cor e Forma:SolidPeso molecular:434.92HER2-IN-11
<p>HER2-IN-11 is a psoralen derivative that induces apoptosis. HER2-IN-11 shows light-activated cytotoxicity and also exhibits anti-breast cancer activity [1].</p>Fórmula:C17H11NO6Cor e Forma:SolidPeso molecular:325.27HDAC-IN-81
CAS:<p>HDAC-IN-81 (Compound 11g) is an HDAC inhibitor capable of effectively inhibiting HDAC1 with an IC50 value of 4.5 nM. Additionally, it exhibits anticancer activity by inhibiting cell proliferation and can induce cell apoptosis (apoptosis).</p>Fórmula:C20H27N3O3Cor e Forma:SolidPeso molecular:357.45BRD-K20733377
CAS:<p>BRD-K20733377 is a Bcl-2 inhibitor that exhibits selective cytotoxicity toward senescent cells, specifically inhibiting the activity of etoposide-induced senescent IMR-90 cells with an IC50 of 10.7 μM. Additionally, BRD-K20733377 reduces the mRNA expression of aging-related genes p16, p21, and KI67 in aged mouse models.</p>Fórmula:C23H18N4O3SCor e Forma:SolidPeso molecular:430.48BRD-K44839765
CAS:<p>BRD-K44839765 selectively targets Bcl-2, exhibiting an IC50 of 5.6 μM in IMR-90 cells. This compound is also orally active.</p>Fórmula:C23H19N3O2S2Cor e Forma:SolidPeso molecular:433.55TBC-1
CAS:<p>TBC-1 is a chlorophyll-a derivative that acts as a photosensitizer for photodynamic therapy (PDT). It efficiently generates type I ROS and targets the endoplasmic reticulum. TBC-1 demonstrates in vitro biocompatibility and PDT effectiveness under both normoxic and hypoxic conditions.</p>Fórmula:C31H28BrN3O3Cor e Forma:SolidPeso molecular:570.476HC-7366
CAS:<p>HC-7366 (GCN2 modulator-1) is an orally active GCN2 kinase activator with antitumor activity, inducing tumor growth inhibition.</p>Fórmula:C20H15ClF2N6O4SPureza:99.84%Cor e Forma:SolidPeso molecular:508.89WEHI-9625
CAS:<p>WEHI-9625 is a tricyclic sulfone small molecule apoptosis inhibitor (EC50: 69 nM).</p>Fórmula:C34H27NO5S2Pureza:98%Cor e Forma:SolidPeso molecular:593.71MLKL-IN-6
<p>MLKL-IN-6 (compound P28) is a mixed lineage kinase inhibitor that specifically targets the Mixed Lineage Kinase domain-like (MLKL) protein.</p>Fórmula:C20H18N4O5Pureza:98%Cor e Forma:SolidPeso molecular:394.38TH-6
<p>TH-6, a potent HDAC inhibitor (IC50: HDAC1-0.115, 2-0.135, 3-0.242, 6-0.138, 8-2.120 μM), blocks cell migration, invasion, and has anti-tumor properties.</p>Fórmula:C22H24FN3O5Cor e Forma:SolidPeso molecular:429.44NSC308848
CAS:<p>NSC308848 is an effective apoptosis (cell death) inducer that operates in a Myc-dependent manner. It acts by inhibiting Myc transactivation and disrupting the DNA binding activity of Myc family proteins.</p>Fórmula:C18H21N3O2Cor e Forma:SolidPeso molecular:311.378Tubulin inhibitor 14
<p>Tubulin inhibitor 14 blocks NQO2 and microtubule formation, disrupts blood vessels, and may target tumors; IC50 of 1.0 μM.</p>Fórmula:C15H9F2NOCor e Forma:SolidPeso molecular:257.23Antitumor agent-77
<p>Antitumor agent-77 suppresses cancer cell growth, migration, induces apoptosis, and hinders EMT.</p>Fórmula:C7H11F3N2O5PtCor e Forma:SolidPeso molecular:455.25NiCur
CAS:<p>NiCur is an effective and selective inhibitor of CBP histone acetyltransferase (HAT), with an IC50 of 0.35 μM.</p>Fórmula:C22H16N2OPureza:99.22%Cor e Forma:SolidPeso molecular:324.38Ivaltinostat formic
<p>Ivaltinostat (CG-200745) is an oral panHDAC inhibitor, inducing apoptosis and enhancing cancer drug sensitivity.</p>Fórmula:C25H35N3O6Cor e Forma:SolidPeso molecular:473.56GRP78-IN-1
<p>GRP78-IN-1 binds to GRP78 protein, inhibits cell growth, and triggers apoptosis in breast cancer; has -8.07 kcal/mol binding energy.</p>Fórmula:C21H23FO3Cor e Forma:SolidPeso molecular:342.4Tubulin polymerization-IN-6
<p>Compound 5f, a potent tubulin polymerization inhibitor (IC50 = 1.09 μM), blocks cell migration, tube formation, and has anti-angiogenic effects.</p>Fórmula:C19H21NO7Cor e Forma:SolidPeso molecular:375.37Spicamycin
CAS:<p>Spicamycin can be used as a potent inducer of differentiation of human myeloid leukemia cells (HL-60) and murine myeloid leukemia cells (M1).</p>Fórmula:C30H51N7O7Cor e Forma:SolidPeso molecular:621.77JAK-2/3-IN-3
<p>JAK-2-/3-IN-3 (ST4j) is a potent JAK2/3 inhibitor for leukemia research, with IC50s: JAK2, 13 nM; JAK3, 14.86 nM; induces apoptosis.</p>Fórmula:C13H10Cl2N4O2Cor e Forma:SolidPeso molecular:325.15p38 MAPK-IN-3
<p>Compound 2c is a potent p38α MAPK inhibitor with antitumor effects, enhancing apoptosis and ROS.</p>Fórmula:C22H17BrO2Cor e Forma:SolidPeso molecular:393.27MA242
CAS:<p>MA242 is a nuclear factor of activated T cells 1 (NFAT1) for Pancreatic Cancer Therapy and dual inhibitor of murine double minute 2 (MDM2).</p>Fórmula:C26H21ClF3N3O5SPureza:98%Cor e Forma:SolidPeso molecular:579.98Metamizole hemimagnesium
CAS:<p>Metamizole (Dipyrone) hemimagnesium is an anti-inflammatory and antioxidant compound known for its ability to reduce fever. It decreases levels of C-reactive protein (CRP) and interleukin 6 (IL-6). Additionally, Metamizole hemimagnesium acts as an orally active cyclooxygenase (COX) inhibitor, suppressing cell proliferation and promoting apoptosis. It is utilized in the study of inflammation and fever.</p>Fórmula:C13H17MgN3O4SCor e Forma:SolidPeso molecular:335.662VEGFR-IN-3
CAS:<p>VEGFR-IN-3 inhibits cancer cell growth (OVCAR-4, MDA-MB-468) with IC50s: 0.29, 0.35μM. Used in cancer research.</p>Fórmula:C27H28N2O6Cor e Forma:SolidPeso molecular:476.52Tubulin inhibitor 41
CAS:<p>Tubulin inhibitor 41 (Compd D19) is a promising lead compound for glioblastoma treatment, known for its ability to penetrate the blood-brain barrier (BBB). It functions as a tubulin inhibitor, inducing G2/M phase arrest, leading to cell apoptosis, and inhibiting the migration of U87 cells [1].</p>Fórmula:C20H15N3OCor e Forma:SolidPeso molecular:313.35Antitumor agent-184
CAS:Antitumor Agent-184 (compound 12aa) triggers apoptosis in various cell lines, exhibiting IC50 values of 2.35 μM in B16-F10 cells, 7.32 μM in 4T1 cells, and 10.31 μM in CT26 cells.Fórmula:C22H16N4O2SCor e Forma:SolidPeso molecular:400.45AKN-028 acetate
<p>AKN-028 acetate: an oral TK inhibitor for AML research, targets FLT3 with IC50 of 6 nM, inhibits autophosphorylation, and induces apoptosis.</p>Fórmula:C19H18N6O2Cor e Forma:SolidPeso molecular:362.39Akt/NF-κB/JNK-IN-1
<p>Akt/NF-κB/JNK-IN-1 (Compound 2i) is an inhibitor of Akt, NF-κB and JNK signalling pathways.Akt/NF-κB/JNK-IN-1 exhibits an inhibitory effect on nitric oxide</p>Fórmula:C22H22N2O6Cor e Forma:SolidPeso molecular:410.42eIF4A3-IN-6
CAS:<p>eIF4A3-IN-6 is a potent eIF4A inhibitor, potentially used for treating eIF4A-related diseases like cancer. (US20170145026A1)</p>Fórmula:C26H25N3O5Cor e Forma:SolidPeso molecular:459.49Ferrostatin-1 diyne
CAS:<p>Ferrostatin-1 diyne (Fer-1 diyne) (compound 2) serves as an inhibitor of ferroptosis, accumulating in cellular lysosomes, mitochondria, and the endoplasmic reticulum. It notably inhibits ferroptosis independently of lysosomal and mitochondrial activity.</p>Fórmula:C18H22N2O2Cor e Forma:SolidPeso molecular:298.38Tandutinib sulfate
CAS:<p>Tandutinib (MLN518) sulfate is an effective and selective inhibitor of FLT3, with an IC50 value of 0.22 μM. It also inhibits c-Kit and PDGFR, displaying IC50 values of 0.17 μM and 0.20 μM respectively. This compound can be utilized in the treatment of acute myeloid leukemia and has the capability to cross the blood-brain barrier.</p>Fórmula:C31H44N6O8SCor e Forma:SolidPeso molecular:660.78XIAP/cIAP1 antagonist-1
<p>Potent oral XIAP/cIAP1 inhibitor with EC50s: XIAP 5.1 nM, cIAP1 0.32 nM; curbs tumor growth in vivo.</p>Cor e Forma:SolidAnticancer agent 64
CAS:<p>Anticancer agent 64 (5m) induces apoptosis, has IC50 2.4μM in CCRF-CEM, activates caspases, cleaves PARP, affects mitochondria.</p>Fórmula:C31H46N2O2SCor e Forma:SolidPeso molecular:510.77BCL6-IN-9
CAS:<p>BCL6-IN-9 (compound 1) is a potent inhibitor of B-cell lymphoma 6 protein (BCL6) (IC50: 3.9 nM) and can be used to study cancer.</p>Fórmula:C22H18ClF2N5O2Cor e Forma:SolidPeso molecular:457.86Topo II/HDAC-IN-2
CAS:<p>Topo II/HDAC-IN-2 (8d) demonstrates remarkable dual inhibitory effects on Topo II and HDAC, and also induces apoptosis [1].</p>Fórmula:C17H20N4O3SCor e Forma:SolidPeso molecular:360.43ER covalent antagonist-1
CAS:<p>ER covalent antagonist-1 (Compound 39D) acts as an antagonist of the estrogen receptor α (ERα). This compound inhibits the proliferation of ERα-positive MCF-7 cells with an IC50 of 0.98 μM, induces cell cycle arrest at the G0/G1 phase, and triggers apoptosis. Additionally, ER covalent antagonist-1 demonstrates antitumor activity in mouse models.</p>Fórmula:C33H32N2O5SCor e Forma:SolidPeso molecular:568.683PAK4-IN-5
<p>PAK4-IN-5 (Compound 12i) is a potent inhibitor of PAK4 (IC50: PAK4 at 7.68 nM, PAK1 at 1872.01 nM) that forms stable interactions with the PAK4 enzyme. This compound effectively inhibits the proliferation and migration potential of MDA-MB-231 cells by hindering the phosphorylation of PAK4 and LIMK1. Additionally, PAK4-IN-5 arrests the cell cycle in the G0/G1 phase, induces apoptosis, and prompts the production of reactive oxygen species. The LD50 in mice is greater than 500 mg/kg (oral).</p>Fórmula:C31H28ClN5OCor e Forma:SolidPeso molecular:522.04Sabialimon P
CAS:<p>Sabialimon P (compound 16), with an IC50 of 18.12 μM, functions as a NO release inhibitor and exhibits anti-inflammatory properties. It effectively diminishes the secretion of TNF-α, iNOS, IL-6, and NF-κB, and suppresses the expression of COX-2 and NF-κB/p65 in LPS-induced RAW264.7 cells.</p>Fórmula:C31H50O4Cor e Forma:SolidPeso molecular:486.73DOR agonist 2
CAS:<p>Compound 3 (DOR agonist 2) acts as a Delta Opioid Receptor agonist. It inhibits the expression of TNF-α, obstructs NF-κB transportation to the nucleus, and activates the G protein-mediated ERK1/2 pathway. This compound is useful for research into neurodegenerative diseases.</p>Fórmula:C29H26N2O3Cor e Forma:SolidPeso molecular:450.53Antiproliferative agent-63
CAS:<p>Antiproliferative agent-63 (compound 4d) is a cyclic analog of cannabidiol that acts as an anticancer agent. It demonstrates favorable activity against breast and colorectal cancer. Moreover, this compound can arrest the cell cycle in the G1 phase and induce apoptosis through the mitochondrial pathway in breast cancer cell lines.</p>Fórmula:C27H41NO2Cor e Forma:SolidPeso molecular:411.62TLBC
CAS:<p>TLBC, a borane-chalcone derivative, exhibits dose-dependent inhibitory effects across various glioma cell lines with IC50 values ranging from 5.5 to 25.5 μM. TLBC induces apoptosis independently of alterations in the tumor suppressor factor p53.</p>Fórmula:C15H12BIO3Cor e Forma:SolidPeso molecular:377.97HDAC6/HSP90-IN-2
<p>HDAC6/HSP90-IN-2, a cancer research chemical, inhibits HDAC6 & Hsp90 with IC50s of 105.7 & 61 nM.</p>Fórmula:C19H22N2O5Cor e Forma:SolidPeso molecular:358.39Ferroptosis-IN-15
CAS:<p>Ferroptosis-IN-15 (compound 12) serves as an effective inhibitor of ferroptosis, exhibiting EC50 values of 0.76 μM and 0.67 μM in A375 cells and 786-O cells, respectively. It acts as a potential iron chelator and radical-scavenging antioxidant.</p>Fórmula:C17H14O5Cor e Forma:SolidPeso molecular:298.29Soquelitinib
CAS:<p>Soquelitinib (CPI-818) is a selective ITK inhibitor， inhibits tumor growth,T-cell, up-regulatCXCR3, IFNγ, TNFα, and CD107a expression in normal CD8 cells.</p>Fórmula:C25H30N4O4S2Pureza:99.54%Cor e Forma:SolidPeso molecular:514.66Oxamic acid
CAS:<p>Oxamic acid is an inhibitor of LDH-A and exhibits antitumor activity. It demonstrates antiproliferative effects on cancer cells and can induce apoptosis.</p>Fórmula:C2H3NO3Cor e Forma:SolidPeso molecular:89.05Z-VAD
CAS:<p>Z-VAD is an irreversible pan-caspase inhibitor, suppressing multiple caspases including caspase-3, -6, -7, -8, and -9. Z-VAD induces autophagy in tumour cells.</p>Fórmula:C20H27N3O8Pureza:98.961%Cor e Forma:SolidPeso molecular:437.443′-Hydroxyflavanone
CAS:<p>3′-Hydroxyflavanone is a cyclized flavonoid with anti-tumor properties that induces apoptosis in HeLa cells.</p>Fórmula:C15H12O3Cor e Forma:SolidPeso molecular:240.25BRD1991
CAS:<p>BRD1991 is a chemical compound that specifically disrupts the interaction between Beclin 1 and Bcl-2, thereby inducing autophagy.</p>Fórmula:C33H35Cl2N3O4Cor e Forma:SolidPeso molecular:608.55PIM-1/HDAC-IN-1
<p>PIM-1/HDAC-IN-1 (4d): inhibits PIM-1 (IC50: 343.87nM), HDAC1 (63.65nM), HDAC6 (62.39nM); induces apoptosis in MCF-7 cells.</p>Fórmula:C22H19N3O3Cor e Forma:SolidPeso molecular:373.4Topo II/HDAC-IN-1
CAS:Topo II/HDAC-IN-1 (7d) demonstrates potent dual inhibitory effects on Topo II and HDAC, while Topo II/HDAC-IN-1 (8d) effectively induces apoptosis [1].Fórmula:C15H16N4O3SCor e Forma:SolidPeso molecular:332.38ZSH-512
CAS:<p>ZSH-512 is a potent inhibitor of RARγ with antiproliferative properties. It induces apoptosis and reduces the expression of CD133, NANOG, SOX2, and EPCAM proteins. ZSH-512 exhibits anticancer activity and shows potential for colorectal cancer research.</p>Fórmula:C20H21N3O3SCor e Forma:SolidPeso molecular:383.464RET-IN-7
CAS:<p>RET-IN-7 exhibits strong inhibitory effects against RET kinase in vitro and shows significant efficacy in treating RET-driven tumor xenografts in mice through</p>Fórmula:C22H24ClFN6O2Cor e Forma:SolidPeso molecular:458.92NA-17
CAS:<p>NA-17 is a naphthalimide compound with antitumor activity and exhibits lower toxicity to normal cells such as HL-7702 and WI-38. It demonstrates p53-dependent inhibition selectivity in various NSCLC cells, inducing the accumulation of active p53 in the mitochondria and nuclei of these cells. NA-17 causes cell cycle arrest in the G1 phase and promotes apoptosis and cell death.</p>Fórmula:C26H27N3O4Cor e Forma:SolidPeso molecular:445.51PD-1-IN-17 TFA
<p>PD-1-IN-17 TFA is a potent PD-1 inhibitor, blocking 92% of splenocyte growth at 100 nM.</p>Fórmula:C15H23F3N6O9Cor e Forma:SolidPeso molecular:488.37Anticancer agent 69
<p>Anticancer agent 69 targets PC3 cells (IC50=26 nM), raises ROS, lowers EGFR, and induces apoptosis.</p>Fórmula:C19H26N8SCor e Forma:SolidPeso molecular:398.53ABL-L
CAS:<p>ABL-L is able to induce apoptosis in human laryngeal cancer cells using a p53-dependent pathway.</p>Fórmula:C29H46O6Cor e Forma:SolidPeso molecular:490.67GLS1 Inhibitor-6
<p>GLS1 Inhibitor-6: IC50=68nM, 220x more selective for GLS2, has anti-tumor and pro-apoptosis effects.</p>Fórmula:C37H52N6O3SCor e Forma:SolidPeso molecular:660.91XIAP degrader-1
<p>XIAP degrader-1 is a small primary amine molecule that promotes the degradation of X-linked apoptosis inhibitory protein (XIAP).</p>Fórmula:C34H45N5O4Cor e Forma:SolidPeso molecular:587.75ERK1/2 inhibitor 11
<p>ERK1/2 inhibitor 11 (compound L6) is a dual inhibitor of ERK1/2 that promotes the accumulation of DSBs and the degradation of ERK1/2 expression. This compound decreases BCL-2 levels and induces DNA damage by inhibiting PARP and ERK1/2. Additionally, ERK1/2 inhibitor 11 activates caspase 3 to induce apoptosis.</p>Fórmula:C15H19N5O2SCor e Forma:SolidPeso molecular:333.41PD-1/PD-L1-IN-15
<p>PD-1/PD-L1-IN-15 is a potent inhibitor of PD-1/PD-L1 (IC50: 60.1 nM) and has shown investigational potential for tumor immunotherapy.</p>Fórmula:C32H30N4O3Cor e Forma:SolidPeso molecular:518.61FLT3-IN-13
<p>FLT3-IN-13 inhibits topoisomerase II/FLT3 in leukemia with IC50 of 2.26 μM, causes G2/M arrest, and promotes apoptosis.</p>Fórmula:C20H14N4O2Cor e Forma:SolidPeso molecular:342.35MLS-0053105
CAS:<p>MLS-0053105, a chloromaleimide, functions as a selective inhibitor of BFL-1, exhibiting an IC50 of 0.4 µM against Bfl-1/F-Bid. Its inhibitory potency is over tenfold lower for Bcl-W, Bcl-2, and Bcl-XL, and it shows no activity against Bcl-B and Mcl-1.</p>Fórmula:C15H14Cl3N3O2Cor e Forma:SolidPeso molecular:374.65ADH-6
CAS:<p>ADH-6, a tripyridylamide, disrupts mutant p53 aggregates in cancer cells, reviving its function and inducing apoptosis.</p>Fórmula:C29H36N8O9Cor e Forma:SolidPeso molecular:640.64ASK1-IN-7
CAS:<p>ASK1-IN-7 (Compound 4c) is an ASK1 inhibitor and a derivative of the ASK1 inhibitor scaffold 5-(5-Phenyl-furan-2-ylmethylene)-2-thioxo-thiazolidin-4-one. This compound is potentially applicable in research involving ASK1 signaling pathways, including studies on cellular stress response, inflammatory response, neurodegenerative diseases, and cardiovascular diseases.</p>Fórmula:C13H8N2O2S2Cor e Forma:SolidPeso molecular:288.345VEGFR-2-IN-15
<p>VEGFR-2-IN-15 (Compound 14b) is a potent inhibitor of VEGFR-2. VEGFR-2-IN-15 inhibits the growth of HepG2 cells in the Pre-G1 phase and induces apoptosis.</p>Fórmula:C23H18ClN3O4SCor e Forma:SolidPeso molecular:467.92N-a-Tosyl-L-lysinyl-chloromethylketone hydrochloride
CAS:<p>N-a-Tosyl-L-lysinyl-chloromethylketone hydrochloride (TLCK hydrochloride) is an irreversible serine protease inhibitor that functions by alkylating the histidine residue at the active site, thus inhibiting trypsin and trypsin-like proteases. It effectively inhibits caspase-3, caspase-6, and caspase-7 with IC50 values of 12.0, 54.5, and 19.3 μM, respectively. Additionally, N-a-Tosyl-L-lysinyl-chloromethylketone hydrochloride induces apoptosis in HL-60 cells and prevents the reduction of mitochondrial transmembrane potential during the apoptosis process.</p>Fórmula:C14H22Cl2N2O3SPeso molecular:369.31GQN-B37-E
CAS:<p>GQN-B37-E is an effective selective binder and inhibitor of MCL-1. It binds to the BH3-binding domain of MCL-1. GQN-B37-E demonstrates binding affinity for MCL-1 within the sub-micromolar range (Ki= 0.6 μM), yet shows negligible binding to BCL-2 or BCL-XL.</p>Fórmula:C29H23ClN4O4Cor e Forma:SolidPeso molecular:526.97EGFR-IN-134
<p>EGFR-IN-134 (compound 3f) is a triazolo[3,4-a]quinoline derivative and functions as a potent EGFR inhibitor with an IC50 of 0.023 µM. It induces apoptosis and necrosis in cells, and causes cell cycle arrest in the G2/M and pre-G1 phases. EGFR-IN-134 modulates the expression of apoptosis-regulating proteins by downregulating anti-apoptotic protein Bcl2 and upregulating pro-apoptotic proteins p53, Bax, and caspases 3, 8, and 9, demonstrating significant antiproliferative and anticancer activities.</p>Fórmula:C36H30N6O5Cor e Forma:SolidPeso molecular:626.66TNF-α-IN-12
CAS:<p>TNF-α-IN-12, a TNF-α inhibitor with an IC50 of 0.1 μM, can reduce TNF-α blood levels [1].</p>Fórmula:C21H22O6Cor e Forma:SolidPeso molecular:370.4PD-1/PD-L1-IN-16
<p>PD-1/PD-L1-IN-16 is a potent inhibitor of PD-1/PD-L1 (IC50: 53.2 nM) and has shown research potential for tumour immunotherapy.</p>Fórmula:C34H30N4O4Cor e Forma:SolidPeso molecular:558.63CK156
CAS:<p>CK156 inhibits DAPK with high selectivity; IC50: 182 nM (DRAK1), 34 μM (CK2a1), 39 μM (CK2a2); key in autoimmune/inflammation research.</p>Fórmula:C21H25N5O3Cor e Forma:SolidPeso molecular:395.45Bomedemstat hydrochloride
<p>Bomedemstat (IMG-7289) hydrochloride, an oral LSD1 inhibitor, has anticancer properties, blocking cell growth and triggering apoptosis.</p>Fórmula:C28H35ClFN7O2Cor e Forma:SolidPeso molecular:556.08Anti-inflammatory agent 16
<p>Compound 14 is a peptidomimetic that significantly lowers TNFα, NO, CD40, and CD86, showcasing strong anti-inflammatory effects.</p>Fórmula:C21H23N5O3Cor e Forma:SolidPeso molecular:393.44Antitumor agent-43
<p>Antitumor agent-43 (Compound 4B) is a potent antitumor agent that induces cell cycle arrest at G2/M phase.</p>Fórmula:C16H8N2O3Cor e Forma:SolidPeso molecular:276.25JAK2/FLT3-IN-1 TFA
<p>JAK2/FLT3-IN-1 (TFA), an oral JAK2/FLT3 inhibitor, shows anticancer properties; IC50: JAK2 (0.7 nM), FLT3 (4 nM), JAK1 (26 nM), JAK3 (39 nM).</p>Fórmula:C27H35F4N7O3Cor e Forma:SolidPeso molecular:581.61GLUT-1-IN-4
CAS:<p>GLUT-1-IN-4 (Compound 13) is an inhibitor of the GLUT-1 glucose transporter that depends on the p53 protein. It suppresses the proliferation of various cancer cells at submicromolar IC50 levels. Additionally, GLUT-1-IN-4 can halt the cell cycle, induce oxidative stress, and promote apoptosis (cell death).</p>Fórmula:C15H10N2O3Cor e Forma:SolidPeso molecular:266.251Mcl-1 inhibitor 9
CAS:<p>Mcl-1 Inhibitor 9 (Example 2) is a potent inhibitor of myeloid cell leukemia 1 (Mcl-1), demonstrating anti-tumor activity with an IC50 value of 0.21889 nM.</p>Fórmula:C32H39ClN2O5SCor e Forma:SolidPeso molecular:599.18GPD-1116
CAS:<p>GPD-1116 is an orally active inhibitor of phosphodiesterase (PDE)4 and PDE1. The compound effectively reduces smoke-induced apoptosis in lung cells. Additionally, GPD-1116 has shown efficacy in various animal disease models, including emphysema, acute lung injury, chronic obstructive pulmonary disease (COPD), asthma, and pulmonary arterial hypertension.</p>Fórmula:C22H16N4OCor e Forma:SolidPeso molecular:352.39Ran-IN-1
CAS:Ran-IN-1 (Compound M36) is an orally active and selective inhibitor of Ran GTPase. It binds allosterically with high specificity to the switch II pocket of GDP-bound Ran (RanGDP), stabilizing its inactive state and reducing the formation of active Ran-GTP. Ran-IN-1 induces apoptosis in epithelial ovarian cancer (EOC) cells and inhibits DNA repair pathways such as homologous recombination (HR) and non-homologous end joining (NHEJ). This compound shows potential for research in epithelial ovarian cancer, particularly in high-grade serous carcinoma.Fórmula:C27H26F3NO4SCor e Forma:SolidPeso molecular:517.56ZLWT-37
<p>ZLWT-37: Oral CDK inhibitor, CDK9 IC50=0.002 µM, CDK2 IC50=0.054 µM; halts HCT116 cells at G2/M, induces apoptosis.</p>Fórmula:C26H30ClN5OCor e Forma:SolidPeso molecular:464GL0388
<p>GL0388, a Bax activator, induces apoptosis, hinders breast cancer growth, and has IC50 of 0.299-1.57 μM.</p>Fórmula:C21H17FN2OCor e Forma:SolidPeso molecular:332.37CP-31398
CAS:<p>CP-31398 stabilizes the active conformation of p53 in cancer cells with either mutated or wild-type p53, enhancing its activity. Additionally, CP-31398 upregulates target genes of p53 such as p21WAF1/Cip1 and KILLER/DR5. This compound possesses tumor-suppressive properties.</p>Fórmula:C22H26N4OCor e Forma:SolidPeso molecular:362.47Necrosis inhibitor 3
CAS:<p>Necrosis Inhibitor 3 (compound B3) effectively inhibits necrosis, demonstrating an IC50 of 0.29 nM in HT29 cells [1].</p>Fórmula:C25H26N4O4SCor e Forma:SolidPeso molecular:478.56MG-B-28
<p>MG-B-28, a BTLA-HVEM inhibitor, demonstrates an IC50 value of 906 nM. It promotes T cell activation dose-dependently by inhibiting the interaction between BTLA and HVEM.</p>Fórmula:C28H25N5O3Cor e Forma:SolidPeso molecular:479.53HER2-IN-10
<p>HER2-IN-10 is a psoralen derivative that induces apoptosis. HER2-IN-10 shows anti-breast cancer activity and light-activated cytotoxicity [1].</p>Fórmula:C15H13NO5Cor e Forma:SolidPeso molecular:287.27Tubulin polymerization-IN-4
CAS:<p>Tubulin polymerization-IN-4: inhibits tubulin (IC50=4.6 μM), blocks G2/M phase, induces apoptosis, hinders cell cloning/migration, damages vasculature.</p>Fórmula:C21H21ClN2O4Cor e Forma:SolidPeso molecular:400.86c-Met/HDAC-IN-2
CAS:<p>Potent dual c-Met/HDAC inhibitor, IC50: HDAC1 5.4 nM, c-Met 18.49 nM; anti-cancer, induces apoptosis, G2/M arrest in HCT-116.</p>Fórmula:C34H33N5O7Cor e Forma:SolidPeso molecular:623.66MTDH-SND1 blocker 2
CAS:<p>MTDH-SND1 blocker 2 (compound C19) is an effective MTDH-SND1 inhibitor with an IC50 value of 487 nM. It binds to the SND1 protein with a Kd of 279 nM and can degrade the SND1 protein. Additionally, MTDH-SND1 blocker 2 exhibits antiproliferative activity and induces apoptosis, showing potential for breast cancer research.</p>Fórmula:C18H12FN3O2SCor e Forma:SolidPeso molecular:353.37Sinulatumolin E
CAS:<p>Sinulatumolin E, a terpenoid, inhibits TNF-α (IC 50: 3.6 μM); has anti-inflammatory properties.</p>Fórmula:C15H22O2Cor e Forma:SolidPeso molecular:234.33Top/HDAC-IN-2
<p>Top/HDAC-IN-2 (45b) is a dual inhibitor of Top and HDAC that induces apoptosis and exhibits significant anti-tumour effects.</p>Fórmula:C30H32N8O4Cor e Forma:SolidPeso molecular:568.63Spliceostatin A
CAS:<p>Spliceostatin A is an anticancer agent and splicing inhibitor that induces apoptosis by inducing cell cycle arrest in the G1 and G2/M phases.</p>Fórmula:C28H43NO8Pureza:94.66%Cor e Forma:SolidPeso molecular:521.643Thalidomide-NH-C5-NH2
CAS:<p>Thalidomide-NH-C5-NH2 is a synthetic E3 ligase ligand-linker conjugate, consisting of a Thalidomide-based cereblon ligand and a linker, used in the synthesis of PROTACs.</p>Fórmula:C18H22N4O4Peso molecular:358.39BRD4/CK2-IN-1
CAS:<p>BRD4/CK2-IN-1 is a small-molecule inhibitor targeting BRD4 and CK2, inducing apoptosis and autophagy-related cell death.</p>Fórmula:C29H30ClN5O5Pureza:99.02%Cor e Forma:SolidPeso molecular:564.03ZLMT-12
<p>ZLMT-12: tacrine derivative, inhibits CDK2/CDK9, weak on AChE/BuChE, anti-proliferative, low toxicity, blocks S/G2/M phase, induces apoptosis.</p>Fórmula:C26H31ClN6OCor e Forma:SolidPeso molecular:479.02BCL6-IN-3
CAS:<p>BCL6-IN-3: potent BCL6 inhibitor, 70 nM GI50 in SU-DHL4, affects cell functions, antitumor.</p>Fórmula:C24H31ClF2N6O2Pureza:98.17%Cor e Forma:SolidPeso molecular:508.99PF-07328948
CAS:<p>PF-07328948 is a branched-chain keto-acid dehydrogenase kinase (BDK) inhibitor, useful for studying CVD metabolic disorders.</p>Fórmula:C16H8F4O3SPureza:98.42%Cor e Forma:SolidPeso molecular:356.29UH15-38
CAS:<p>UH15-38 is a potent and selective RIPK3 inhibitor that blocks necroptosis in alveolar epithelial cells triggered by IAV, useful for studying lung inflammation.</p>Fórmula:C26H27N5O2Pureza:99.85%Cor e Forma:SolidPeso molecular:441.53SY-5609
CAS:<p>SY-5609 (CDK7-IN-3) is a selective non-covalent CDK7 inhibitor, with weak inhibitory activity against CDK2, CDK9 and CDK12.Cost-effective and quality-assured.</p>Fórmula:C23H26F3N6OPPureza:99.34% - >99.99%Cor e Forma:SolidPeso molecular:490.46Tuvusertib
CAS:<p>Tuvusertib (M1774), an oral ATR inhibitor (Ki<1µM), selectively blocks CHK1 phosphorylation, disrupts DNA repair, and induces tumor cell apoptosis.</p>Fórmula:C16H12F2N8OPureza:98.44% - 99.66%Cor e Forma:SolidPeso molecular:370.32HC-5404
CAS:<p>HC-5404 is a potent and selective PERK inhibitor, blocking the activation of the PERK pathway, anti-tumor effects, advanced solid tumors and renal cell Cancer.</p>Fórmula:C24H24F2N4O3Pureza:99.33%Cor e Forma:SolidPeso molecular:454.47Vatalanib hydrochloride
CAS:<p>Vatalanib hydrochloride (PTK787 hydrochloride) is an orally available and highly potent tyrosine kinase (VEGF) inhibitor that reduces the number and size of Aβ plaques in the cortex of 5xFAD mice, which may be useful in the study of Alzheimer's disease and cancer.</p>Fórmula:C20H16Cl2N4Pureza:99.7%Cor e Forma:SolidPeso molecular:383.27Lometrexol
CAS:<p>Lometrexol (LY 264618) is an antifolate that inhibits GARFT, blocks purine synthesis, induces apoptosis, and has anticancer properties.</p>Fórmula:C21H25N5O6Pureza:97.76% - 99.56%Cor e Forma:SolidPeso molecular:443.45Milademetan
CAS:<p>Milademetan (DS-3032), an MDM2 inhibitor, exhibits antitumor activity, induces G1 cell cycle arrest and apoptosis, and can be used to study solid tumors.</p>Fórmula:C30H34Cl2FN5O4Pureza:>99.99%Cor e Forma:SolidPeso molecular:618.53Zotatifin
CAS:<p>Zotatifin (eFT226) is a selective eIF4A inhibitor with antiviral and antitumor properties, inhibiting Sox4 translation and inducing apoptosis.</p>Fórmula:C28H29N3O5Pureza:98.85%Cor e Forma:SolidPeso molecular:487.55Gemcitabine elaidate hydrochloride
CAS:<p>CP-4126, a lipophilic pro-drug of Gemcitabine, converts to active form by esterases, allowing oral administration with dose-dependent effects.</p>Fórmula:C27H44ClF2N3O5Pureza:98.50% - 99.6%Cor e Forma:SolidPeso molecular:564.11JAK2-IN-7
CAS:<p>JAK2-IN-7 selectively inhibits JAK2 (IC50: 3 nM), shows 14-fold selectivity over JAK1/3, FLT3, induces G0/G1 arrest, apoptosis, and has antitumor effects.</p>Fórmula:C26H33N7OPureza:99.54%Cor e Forma:SolidPeso molecular:459.59FX-11
CAS:<p>FX-11: potent LDHA inhibitor (Ki 8 μM), activates PKM2, reduces ATP, induces oxidative stress/ROS, cell death, shows antitumor effects.</p>Fórmula:C22H22O4Pureza:98.95%Cor e Forma:SolidPeso molecular:350.41Actinonin
CAS:<p>Actinonin ((-)-Actinonin) is a naturally occurring antibacterial agent produced by Actinomyces and a potent reversible peptide deformylase (PDF) inhibitor with a Ki of 0.28 nM. It also induces apoptosis and inhibits aminopeptidase M, aminopeptidase N, and leucine aminopeptidase, as well as MMP-1, MMP-3, MMP-8, MMP-9, and meprin α with Ki values of 300 nM, 1,700 nM, 190 nM, 330 nM, and 20 nM, respectively. Actinonin exhibits antiproliferative and antitumor activities [1][2][3][4][5].</p>Fórmula:C19H35N3O5Cor e Forma:SolidPeso molecular:385.5OBAA
CAS:<p>OBAA is a potent inhibitor of phospholipase A2 (PLA2) with an IC 50 of 70 nM. OBAA blocks Melittin-induced Ca 2+ influx in Trypanosoma brucei with an IC 50 of 0.4 μM [1] [2] [3].</p>Fórmula:C28H44O3Pureza:98%Cor e Forma:SolidPeso molecular:428.65β-Zearalanol
CAS:Beta-Zearalenol, a derivative of zearalenone (ZEA) capable of conjugating with glucuronic acid[2], is a mycotoxin produced by Fusarium spp. It induces apoptosis and oxidative stress in mammalian reproductive cells[1].Fórmula:C18H26O5Cor e Forma:SolidPeso molecular:322.4(R)-Verapamil hydrochloride
CAS:<p>(R)-Verapamil hydrochloride ((R)-(+)-Verapamil hydrochloride) is an inhibitor of P-Glycoprotein.</p>Fórmula:C27H39ClN2O4Cor e Forma:SolidPeso molecular:491.06PIM-447 dihydrochloride
CAS:<p>PIM-447 dihydrochloride is an orally available and selective inhibitor of pan-PIM kinase(Ki values of 6, 18, and 9 pM for PIM1, PIM2, and PIM3, respectively).</p>Fórmula:C24H25Cl2F3N4OPureza:98%Cor e Forma:SolidPeso molecular:513.38WEHI-539 hydrochloride
CAS:<p>WEHI-539 hydrochloride is a selective Bcl-XL inhibitor with an IC50 of 1.1 nM.</p>Fórmula:C31H30ClN5O3S2Pureza:98%Cor e Forma:SolidPeso molecular:620.18AP1867-3-(aminoethoxy)
CAS:<p>AP1867-3-(aminoethoxy) is a synthetic ligand for FKBP and can be used in the synthesis of PROTAC FKBP12 F36V degrader.</p>Fórmula:C38H50N2O9Cor e Forma:SolidPeso molecular:678.81Platinum, diammine[1,1-cyclobutanedi(carboxylato-kO)(2-)]-, (SP-4-2)-
CAS:Fórmula:C6H10N2O4PtPureza:98%Cor e Forma:SolidPeso molecular:369.2326Ref: IN-DA00I84B
Produto descontinuado5-Amino-1-β-D-ribofuranosyl-1H-imidazole-4-carboxamide
CAS:Fórmula:C9H14N4O5Pureza:95%Cor e Forma:SolidPeso molecular:258.2313Ac-IETD-CHO TFA
<p>Ac-IETD-CHO TFA is a granzyme B and caspase-8 inhibitor that inhibits caspase8 activity by blocking caspase3 precursor cleavage.Ac-IETD-CHO TFA inhibits Fas-mediated apoptosis.</p>Fórmula:C23H35F3N4O12Cor e Forma:SoildPeso molecular:616.54ENMD-2076 tartrate
CAS:<p>ENMD-2076 is an orally active kinase inhibitor. It also has antiangiogenic and antiproliferative mechanisms of action.</p>Fórmula:C25H31N7O6Cor e Forma:SolidPeso molecular:525.56Thalidomide-O-amido-C4-NH2 hydrochloride
CAS:<p>Thalidomide-O-amido-C4-NH2 hydrochloride, a synthesized E3 ligase ligand-linker conjugate, combines the cereblon ligand derived from Thalidomide with a linker and is commonly used in the synthesis of PROTACs[1].</p>Fórmula:C19H23ClN4O6Pureza:98%Cor e Forma:SolidPeso molecular:438.86Ciprofloxacin lactate
CAS:<p>Ciprofloxacin lactate is a useful organic compound for research related to life sciences. The catalog number is T66299 and the CAS number is 97867-33-9.</p>Fórmula:C20H24FN3O6Cor e Forma:SolidPeso molecular:421.43SCH79797
CAS:<p>SCH79797 is a potent and specific protease-activated receptor 1 (PAR1) antagonistwith antimicrobial, anticancer, anti-inflammatory, and neuroprotective effects.</p>Fórmula:C23H25N5Pureza:99.80%Cor e Forma:SolidPeso molecular:371.48Thalidomide-5-COOH
CAS:<p>Thalidomide-5-COOH is a useful organic compound for research related to life sciences. The catalog number is T64600 and the CAS number is 1216805-11-6.</p>Fórmula:C14H10N2O6Cor e Forma:SolidPeso molecular:302.242MI-773
CAS:<p>MI-773 is a potent inhibitor of the MDM2-p53 protein interaction (PPI) with a high affinity for MDM2 and a Kd value of 8.2 nM. MI-773 exhibits antitumour effects.</p>Fórmula:C29H34Cl2FN3O3Cor e Forma:SolidPeso molecular:562.5Thalidomide-O-C5-NH2 hydrochloride
CAS:<p>Thalidomide-O-C5-NH2 hydrochloride is a synthetic compound consisting of a ligand-linker conjugate with E3 ligase activity. It combines a cereblon ligand based on Thalidomide and a linker commonly utilized in PROTAC technology.</p>Fórmula:C18H22ClN3O5Cor e Forma:SolidPeso molecular:395.84Thalidomide-O-C6-COOH
CAS:<p>Thalidomide-O-C6-COOH is a synthetic conjugate that combines a Thalidomide-derived cereblon ligand with a PROTAC technology linker (E3 ligase ligand-linker).</p>Fórmula:C20H22N2O7Cor e Forma:SolidPeso molecular:402.403RRD-251
CAS:<p>RRD-251 is an Rb-Raf-1 interaction inhibitor that induces apoptosis in metastatic melanoma cells and synergizes with dacarbazine[1].</p>Fórmula:C8H9Cl3N2SCor e Forma:SolidPeso molecular:271.59Ingenol 3,20-dibenzoate
CAS:<p>Ingenol 3,20-dibenzoate is a powerful activator of protein kinase C (PKC) isoforms that effectively induces the translocation of nPKC-delta, -epsilon, and -theta, as well as PKC-mu, from the cytosolic fraction to the particulate fraction. Through de novo synthesis of macromolecules, it triggers apoptosis with characteristic morphology. Moreover, Ingenol 3,20-dibenzoate enhances IFN-γ production and degranulation in NK cells, particularly when stimulated by NSCLC cells[1][2].</p>Fórmula:C34H36O7Cor e Forma:SolidPeso molecular:556.65Carubicin hydrochloride
CAS:<p>Carubicin HCl is an anthracycline antineoplastic antibiotic. Through intercalates into DNA and interacts with topoisomerase II, Carubicin inhibits DNA replication and repair and RNA and protein synthesis.</p>Fórmula:C26H28ClNO10Cor e Forma:SolidPeso molecular:549.95A-192621
CAS:<p>A-192621 is a potent, nonpeptide, orally active, and selective endothelin B (ETB) receptor antagonist with an IC50 of 4.5 nM and a Ki of 8.8 nM. A-192621 promotes apoptosis in PASMCs and elevates both arterial blood pressure and plasma ET-1 levels[1][2][3]. Its selectivity is 636-fold higher for ETB than ETA (IC50 of 4280 nM and Ki of 5600 nM).</p>Fórmula:C33H38N2O6Pureza:98%Cor e Forma:SolidPeso molecular:558.66Yatein
CAS:<p>Yatein inhibits herpes simplex virus type 1 replication by interruption the immediate-early gene expression. Yatein is a lignan isolated from A. chilensis. It also has antiproliferative activity.</p>Fórmula:C22H24O7Pureza:98%Cor e Forma:SolidPeso molecular:400.42Mcl-1 inhibitor 6
CAS:<p>Mcl-1 inhibitor 6 binds Mcl-1 with KD 0.23 nM and Ki 0.02 μM, shows strong selectivity over Bcl-2 family, and demonstrates antitumor efficacy.</p>Fórmula:C26H28ClNO6SCor e Forma:SolidPeso molecular:518.02XMU-MP-3
CAS:<p>XMU-MP-3 is a robust, non-covalent inhibitor of BTK, exhibiting exceptional potency with IC50 values of 10.7 nM and 17.0 nM for BTK WT and BTK C481S mutation, respectively, in the presence of 10 μM ATP. Moreover, XMU-MP-3 elicits apoptosis.</p>Fórmula:C27H27F3N8OCor e Forma:SolidPeso molecular:536.563Imifoplatin
CAS:<p>Imifoplatin (PT-112) is a platinum compound with antitumor activity and may be used to study prostate cancer and immune system disorders.</p>Fórmula:C6H16N2O7P2PtPureza:≥95.0%Cor e Forma:SolidPeso molecular:485.23Prostaglandin A2
CAS:<p>PGA2 is a naturally occurring prostaglandin in gorgonian corals where it may function in self defense. It is generally not present in mammals. PGA2 has low biological potency in most bioassays, but it does show some antiviral/antitumor activity.[1] At a 25 uM concentration, PGA2 blocks the cell cycle progression of NIH 3T3 cells at the G1 and G2/M phase .[2] It has also been shown to act as a vasodilator with natriuretic properties.[3]</p>Fórmula:C20H30O4Cor e Forma:SolidPeso molecular:334.45DB818
CAS:<p>DB818 is a synthetic Homeobox A9 (HOXA9) inhibitor and can be used for research on the treatment of acute myeloid leukaemia associated with HOXA9 overexpression.</p>Fórmula:C19H16N6SPureza:98%Cor e Forma:SolidPeso molecular:360.44Vatiquinone
CAS:<p>Vatiquinone, also known as EPI 743, is an orally bioavailable para-benzoquinone being developed for inherited mitochondrial diseases. The mechanism of action of EPI-743 involves augmenting the synthesis of glutathione, optimizing metabolic control, enhanc</p>Fórmula:C29H44O3Cor e Forma:SolidPeso molecular:440.66Swainsonine
CAS:<p>Swainsonine (Tridolgosir) is an alkaloid isolated from Astragalus membranaceus and is a potent and reversible inhibitor of alpha-mannosidase. swainsonine has antitumour activity and induces apoptosis and cell cycle arrest in the G2/M phase.</p>Fórmula:C8H15NO3Pureza:98%Cor e Forma:Lyophilized PowderPeso molecular:173.21CTB
CAS:<p>CTB (Cholera Toxin B subunit) is an activator of p300 histone acetyltransferase and induces apoptosis in MCF-7 cells.</p>Fórmula:C16H13ClF3NO2Pureza:99.82%Cor e Forma:SolidPeso molecular:343.73anti-TNBC agent-2
CAS:<p>Anti-TNBC agent-2 (3j), a purine derivative, acts as an anti-triple negative breast cancer (TNBC) therapeutic.</p>Fórmula:C28H37ClFN7OPureza:98%Cor e Forma:SolidPeso molecular:542.09Ref: TM-T79699
Produto descontinuadoSMIP34
CAS:<p>SMIP34 is an inhibitor of PELP1 that demonstrates the capability to reduce cell viability and colony formation. Additionally, SMIP34 induces cell apoptosis (apoptosis) and causes cell cycle arrest in the S phase. It reduces the expression of PELP1 and exhibits anti-tumor activity. SMIP34 also has potential for research in triple-negative breast cancer (TNBC).</p>Fórmula:C20H15ClFN5O2SCor e Forma:LiquidPeso molecular:443.88Taltobulin
CAS:<p>Taltobulin (HTI-286) is a synthetic analog of the tripeptide cysteine, a microtubule protein inhibitor that inhibits liver tumor cell proliferation in vitro and tumor growth in vivo.Taltobulin is cytotoxic, induces mitotic arrest and apoptosis, and may be used in the study of breast cancer and microtubule tissue-related diseases.</p>Fórmula:C27H43N3O4Pureza:99.86%Cor e Forma:SolidPeso molecular:473.65IHMT-MST1-39
CAS:<p>IHMT-MST1-39 is an orally effective MST kinase inhibitor with IC50 values of 42 nM for MST1 and 109 nM for MST2. It activates the AMPK signaling pathway in hepatocytes and inhibits apoptosis in pancreatic β cells. Additionally, IHMT-MST1-39 improves type 1 diabetes in mice induced by Streptozotocin.</p>Fórmula:C20H18F2N6O3SCor e Forma:SolidPeso molecular:460.46Ref: TM-T200512
Produto descontinuadoZSQ836
CAS:<p>ZSQ836 is a dual covalent inhibitor of CDK12/CDK13 with oral bioactivity, displaying an EC50 value of 32 nM against CDK12. This compound can induce cell apoptosis (apoptosis) and demonstrates in vivo anticancer properties. ZSQ836 is applicable for research in ovarian cancer.</p>Fórmula:C27H28AsClN6OS2Cor e Forma:SolidPeso molecular:627.05Ref: TM-T200333
Produto descontinuadoDETD-35
CAS:<p>DETD-35 is a promising chemical compound in anti-melanoma therapy, functioning as an inhibitor of the MEK-ERK, Akt, and STAT3 signaling pathways. It enhances cancer cell apoptosis (Apoptosis) and diminishes resistance to Vemurafenib in cancer cells. The compound exhibits IC 50 values of 2.7, 6.0, 3.9, 3.1, and 2.5 μM against melanoma cell lines B16-F10, MeWo, SK-MEL-2, A2058c, and A375c, respectively. DETD-35 offers significant potential for advancing research in melanoma treatment strategies.</p>Fórmula:C27H24O6Cor e Forma:SolidPeso molecular:444.48CHMFL-48
CAS:<p>CHMFL-48, an orally active inhibitor of BCR-ABL kinase, demonstrates efficacy against both the wild-type (wt) and various imatinib-resistant mutants. It exhibits potent inhibitory activity, with IC 50 values of 1 nM for the ABL wild-type and 0.8 nM for the ABL T315I mutant. CHMFL-48 operates by inhibiting the autophosphorylation of both wild-type and mutant BCR-ABL, affecting downstream signaling mediators including STAT5 and CRKL. This disruption leads to cell cycle arrest and triggers apoptosis. Given its properties, CHMFL-48 is a promising candidate for research on chronic myeloid leukemia (CML).</p>Fórmula:C31H30F3N7OCor e Forma:SolidPeso molecular:573.61Cyy-272
CAS:<p>Cyy-272 is an orally active JNK inhibitor with IC50 values of 1.25, 1.07, and 1.24 μM against JNK1, JNK2, and JNK3, respectively. It exerts anti-inflammatory effects by inhibiting the phosphorylation of JNK, thereby alleviating acute lung injury (ALI) induced by lipopolysaccharide (LPS). Moreover, Cyy-272 significantly reduces inflammation in cardiomyocytes and cardiac tissues caused by high lipid concentrations, further mitigating resultant cardiac hypertrophy, fibrosis, and apoptosis. Cyy-272 is utilized in the study of obesity-related myocarditis.</p>Fórmula:C23H23F2N7Cor e Forma:SolidPeso molecular:435.47Ref: TM-T200453
Produto descontinuado
![Platinum, diammine[1,1-cyclobutanedi(carboxylato-kO)(2-)]-, (SP-4-2)-](/_next/image/?url=https%3A%2Fstatic.cymitquimica.com%2Fproducts%2FIN%2Fthumb-webp%2FDA00I84B.webp&w=3840&q=75)
